Study S001769

Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02650596
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 68
Start: 2016-01
Primary completion: 2018-02
Lead sponsor: Shi Yang
Conditions: Heart Failure
Interventions: DRUG:GLP-1; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

left ventricular ejection fraction measured by 3D echocardiography [3 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025982	Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Chen WR, Endocrine	2016	Randomized trial	PMID 26573925 DOI	registry reference RESULT:26573925
R0020721	Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Chen WR, American heart journal	2015	Randomized trial	PMID 26542491 DOI	registry reference RESULT:26542491
R0025460	Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Timmers L, Journal of the American College of Cardiology	2009	Randomized trial	PMID 19195607 DOI	registry reference BACKGROUND:19195607